The majority of colorectal cancer cells (53%) show mutation on KRAS, being characterized by the activation of both mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling pathways28. This evidence concerns the gene WNK2 and colorectal cancer.